NICE has completed a rapid evidence summary on the off-label use of eculizumab (Soliris, Alexion Pharma UK) for managing dense deposit disease (DDD), a form of the rare kidney condition C3 glomerulopathy. 

Although there was no evidence for the use of eculizumab after a kidney transplant to prevent the disease recurring, there were a small number of cases where the drug was used to stop the progression of the disease when it had recurred. 

The NICE evidence summary considers the published international evidence of eculizumab’s effectiveness, safety, cost and patient factors in determining whether prophylactic use of eculizumab is effective and safe for preventing recurrence of C3 glomerulopathy after kidney transplantation. It is not formal NICE guidance but is intended to inform NHS England’s decision on the use of the drug to prevent recurrence of dense deposit disease in people who have had a kidney transplant.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-publishes-evidence-summary-on-eculizumab-soliris-for-treating-rare-kidney-condition